To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF.
Potential upside to average price target of more than 40%.
Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics .
Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals .
Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.
Persons:
Marinus, Biomea
Organizations:
Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals